Figure 2
From: Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography
[18F]Fluorodeoxyglucose (18F-FDG) (a) and 16α-[18F]fluoro-17β-estradiol (18F-FES) (b) positron-emission tomography (PET) studies obtained in a patient with newly diagnosed metastatic recurrent breast cancer in the bones. The bone metastases are readily seen in both studies. Whereas 18F-FDG-PET images provide information about the metabolic activity of the metastases, 18F-FES images can demonstrate that the recurrent lesions still express high levels of estrogen receptors.